LONDON, United Kingdom, June 24, 2026 — RQ Bio, a private biotechnology company developing long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations, today announced the completion of an oversubscribed $115 million (£85.5 million) Series A financing. The financing was led by Frazier Life Sciences, with participation from new investors EQT Life Sciences, Forbion, Monograph and Wellington Management alongside founding investor LifeArc Ventures, as well as shareholders Oxford Science Enterprises and the University of Oxford.